View Exam | PowerPak

1. Which of the following is the approved indication for selinexor?

A. First-line therapy B. Relapsed/refractory disease in patients that have failed at least two prior lines of therapy C. Relapsed/refractory disease in patients that have failed at least four prior lines of therapy D. Maintenance therapy

2. Which approach is the current standard in individuals with newly diagnosed multiple myeloma and significant comorbidities?

A. Monotherapy B. Doublet therapy C. Triplet therapy D. Four-drug regimen

3. Which of the medications below are associated with significant risk of infusion reactions?

A. Bortezomib, elotuzumab B. Daratumumab, selinexor C. Elotuzumab, daratumumab D. Selinexor, bortezomib

4. A 56-year-old male with multiple myeloma was previously treated with bortezomib and lenalidomide. His disease has recurred and he will be starting treatment with elotuzumab. Which pre-treatment medications should he receive?

A. Acetaminophen, diphenhydramine, ranitidine, dexamethasone B. An antipyretic and an antihistamine C. Dexamethasone and ranitidine D. Diphenhydramine, acetaminophen, and an antipyretic

5. A 70-year-old woman with newly diagnosed multiple myeloma is being treated with doublet therapy due to her age and the presence of comorbidities. Which of the supportive care options below should she receive?

A. An antihistamine B. An antipyretic C. A bisphosphonate D. Dexamethasone

6. The NCCN recommends pharmacologic thromboprophylaxis for all patients being treated with which class of agents?

A. CAR-T therapies B. Exportin-1 inhibitors C. Immunomodulatory agents D. Protease inhibitors

7. When should a 73-year old man with multiple myeloma be treated prophylactically to reduce the risk of disseminated herpes?

A. If he is treated with a bortezomib-based regimen, high-dose dexamethasone, and daratumumab B. If he is treated with lenalidomide-based regimen C. If he is treated with selinexor D. Any of the above regimens

8. Based upon the monograph discussion, which of the following is a solution the busy interprofessional team can implement to reduce the risk of errors in a patient's treatment plan?

A. Arrange a 1-hour conference call every other week B. Develop a database of approved regimens C. Develop a standard checklist for each treatment plan D. Review the plan together each week

9. Which of the medications below might be the cause of the patient's peripheral neuropathy?

A. Bortezomib, dexamethasone B. Bortezomib, lenalidomide C. Dexamethasone, lenalidomide D. Any of these could cause neuropathy

10. What would be a first step to alleviate the patient's peripheral neuropathy?

A. Administer bortezomib subcutaneously B. Discontinue lenalidomide C. Reduce the dose of dexamethasone D. Prescribe topical corticosteroids

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is the approved indication for selinexor?

2. Which approach is the current standard in individuals with newly diagnosed multiple myeloma and significant comorbidities?

3. Which of the medications below are associated with significant risk of infusion reactions?

4. A 56-year-old male with multiple myeloma was previously treated with bortezomib and lenalidomide. His disease has recurred and he will be starting treatment with elotuzumab. Which pre-treatment medications should he receive?

5. A 70-year-old woman with newly diagnosed multiple myeloma is being treated with doublet therapy due to her age and the presence of comorbidities. Which of the supportive care options below should she receive?

6. The NCCN recommends pharmacologic thromboprophylaxis for all patients being treated with which class of agents?

7. When should a 73-year old man with multiple myeloma be treated prophylactically to reduce the risk of disseminated herpes?

8. Based upon the monograph discussion, which of the following is a solution the busy interprofessional team can implement to reduce the risk of errors in a patient's treatment plan?

9. Which of the medications below might be the cause of the patient's peripheral neuropathy?

10. What would be a first step to alleviate the patient's peripheral neuropathy?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is the approved indication for selinexor?

2. Which approach is the current standard in individuals with newly diagnosed multiple myeloma and significant comorbidities?

3. Which of the medications below are associated with significant risk of infusion reactions?

4. A 56-year-old male with multiple myeloma was previously treated with bortezomib and lenalidomide. His disease has recurred and he will be starting treatment with elotuzumab. Which pre-treatment medications should he receive?

5. A 70-year-old woman with newly diagnosed multiple myeloma is being treated with doublet therapy due to her age and the presence of comorbidities. Which of the supportive care options below should she receive?

6. The NCCN recommends pharmacologic thromboprophylaxis for all patients being treated with which class of agents?

7. When should a 73-year old man with multiple myeloma be treated prophylactically to reduce the risk of disseminated herpes?

8. Based upon the monograph discussion, which of the following is a solution the busy interprofessional team can implement to reduce the risk of errors in a patient's treatment plan?

9. Which of the medications below might be the cause of the patient's peripheral neuropathy?

10. What would be a first step to alleviate the patient's peripheral neuropathy?

« Return to Activity

Customers who Purchased
this Activity also Purchased